Amit Mehta, MD

home / authors / amit-mehta-md

Articles

Future of R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

March 2nd 2023

A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.

Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

March 2nd 2023

Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.

Sequencing Therapies in Patients with R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 22nd 2023

Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.

ZUMA-7: Clinical Implications

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 22nd 2023

Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.

Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 15th 2023

An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.

Role of CAR T-cell Therapy in Patients with R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 15th 2023

Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.

L-MIND: Review of Long-Term Analyses Data

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 8th 2023

Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.

Treatment Options for Patients with R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 8th 2023

Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.

An Overview of R/R DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 1st 2023

Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).

Front-Line Treatment Options for Patients with DLBCL

Matthew Lunning, DO, FACP;Ann Mohrbacher, MD;Amit Mehta, MD;David Miklos, MD;Joshua Brody, MD, of Mount Sinai Hospital

February 1st 2023

Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).